Ginkgo (DNA) CFO Coen Sells 330 Shares

What Happened

• Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks (DNA), had restricted stock units (RSUs) vest and converted to common shares on August 21, 2026 (reported as "exercise or conversion of derivative" transactions). A subsequent open-market sale on August 24, 2026 disposed of 330 shares at $6.98 per share, generating $2,302.
• The filing also reports the acquisition (vesting) of 587 shares and 156 shares on August 21, 2026, and corresponding disposals of those same amounts as derivative transactions — these disposals reflect shares used to satisfy withholding obligations, not discretionary selling.

Key Details

• Transaction dates and prices:
  • 2026-08-21: RSU conversions/vests (587 shares and 156 shares) (no price listed for vesting).
  • 2026-08-24: Open-market sale of 330 shares at $6.98 each, proceeds $2,302.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Each RSU converts to one share of Class A common stock.
  • F2: Some shares were sold to cover tax withholding; these "sell to cover" actions are allowed under the company’s equity plans and are not considered discretionary trades.
  • F3/F4: RSU vesting schedules noted (initial 25% or 2/48ths vested May 1, 2024, with remaining vesting in equal monthly installments).
• Filing timing: Form 4 was filed August 25, 2026 reporting transactions on August 21–24; no late-filing flag was indicated in the provided data.

Context

• The August 21 entries are conversions/vests of RSUs (derivative-to-stock conversion). The disposals tied to those conversions were to cover tax withholding — a routine, plan-authorized administrative step rather than a discretionary sale for investment reasons.
• This transaction is small in dollar terms (~$2.3k) and primarily reflects routine vesting and tax-related share sales by the CFO, not a large open-market exit.